Emergent BioSolutions Inc

16 de set. de 2026, 20:07 UTC

Emergent BioSolutions Inc shares are significantly higher, maintaining strong performance from Tuesday, despite pulling back slightly after reaching a midday high.

15 de set. de 2026, 19:16 UTC

Emergent BioSolutions Inc shares are lower as the company cuts 90 jobs and restructures to save $40 million amid rising treasury yields and inflation concerns.

11 de set. de 2026, 20:01 UTC

Emergent BioSolutions Inc shares are higher, following a recent decline in the Michigan Consumer Sentiment Index, which fell to 47.8, below expectations.

10 de set. de 2026, 20:03 UTC

Emergent BioSolutions shares are higher today, supported by a consensus "Hold" rating and reaffirmed buy ratings from UBS and Benchmark. The average target price is $10.00.

9 de set. de 2026, 20:02 UTC

Emergent BioSolutions Inc shares are lower today, continuing a decline since Tuesday's close. No specific news was identified to explain the movement.

8 de set. de 2026, 20:08 UTC

Emergent BioSolutions Inc shares are lower following a downgrade to Hold amid concerns over declining revenues and ongoing debt issues.

3 de set. de 2026, 20:03 UTC

Emergent BioSolutions faces investigation amid $191.3 million impairment charge and $180.2 million net loss, contributing to shares trading lower today.

2 de set. de 2026, 19:53 UTC

Emergent BioSolutions Inc. is under investigation related to recent financial disclosures, following a significant net loss and reduced revenue guidance. Shares are higher today.

1 de set. de 2026, 20:09 UTC

Emergent BioSolutions secures a $24 million contract modification from BARDA for its anthrax vaccine, CYFENDUS®, as shares rise in Tuesday trading.

31 de ago. de 2026, 20:02 UTC

Emergent BioSolutions secures a Canadian government contract for NARCAN® Nasal Spray, boosting shares during Monday's session. The agreement runs from October 2026 to September 2029.

28 de ago. de 2026, 20:07 UTC

Emergent BioSolutions shares are lower amid an investigation by Bronstein, Gewirtz & Grossman, LLC, following a $191.3 million impairment charge and reduced revenue guidance.

27 de ago. de 2026, 20:07 UTC

Emergent BioSolutions Inc. is under investigation, following a $180.2 million net loss and reduced revenue guidance, contributing to a decline in shares today.

26 de ago. de 2026, 20:08 UTC

Emergent BioSolutions Inc shares are higher, reflecting strong upward momentum since Tuesday. The stock remains well above its 20-day moving average.

25 de ago. de 2026, 20:07 UTC

Emergent BioSolutions Inc shares are higher during Tuesday's session, continuing a strong advance since Monday's close amid easing Treasury yields and lower oil prices.

24 de ago. de 2026, 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a cumulative increase since Friday. The stock remains below its 20-day moving average.

21 de ago. de 2026, 19:51 UTC

Emergent BioSolutions Inc shares are higher today, continuing a steady upward trend since Thursday's close. No specific news was identified to explain the movement.

20 de ago. de 2026, 19:02 UTC

Emergent BioSolutions Inc faces scrutiny after a $191.3 million impairment charge and a reduced revenue outlook, contributing to a decline in shares.

19 de ago. de 2026, 19:52 UTC

Emergent BioSolutions Inc is trading higher during Wednesday's session, recovering from earlier lows and reflecting strength since Tuesday's close. No specific news was identified.

18 de ago. de 2026, 20:06 UTC

Emergent BioSolutions Inc shares are higher today, reflecting a broader market recovery. The stock remains below its 20-day moving average and prior month levels.

17 de ago. de 2026, 19:56 UTC

Emergent BioSolutions faces investigations over financial disclosures, including a $191.3 million impairment charge, contributing to lower shares amid declining investor confidence.

13 de ago. de 2026, 19:51 UTC

Emergent BioSolutions Inc shares are roughly flat as jobless claims rise to 209,000, exceeding expectations. The stock remains below its 20-day moving average.

12 de ago. de 2026, 19:26 UTC

Emergent BioSolutions Inc gains amid broader market optimism following inflation data. The stock reached a session high before slightly pulling back.

11 de ago. de 2026, 22:56 UTC

Emergent BioSolutions Inc shares are trading lower in after-market hours. No specific news was identified to explain the movement.

10 de ago. de 2026, 19:51 UTC

Emergent BioSolutions shares are trading lower as H.C. Wainwright reduced its price target to $10.00, citing concerns over performance and outlook amid competitive pressures.

7 de ago. de 2026, 23:26 UTC

Emergent BioSolutions Inc shares rose in after-market trading, amid positive market sentiment and notable gains in major tech stocks. No specific news was identified.

6 de ago. de 2026, 23:41 UTC

Emergent BioSolutions traded roughly flat after market hours, with no specific news identified. The stock has declined significantly over the past month.

5 de ago. de 2026, 22:51 UTC

Emergent BioSolutions shares are lower in after-market hours following a Q2 net loss of $180.2 million and reduced full-year sales guidance.

29 de jul. de 2026, 19:56 UTC

Emergent BioSolutions Inc shares are trading higher Wednesday, reflecting gains since Tuesday's close, despite earlier fluctuations and broader market pressures.

27 de jul. de 2026, 18:46 UTC

Emergent BioSolutions Inc shares are higher amid a broader market trend, despite pulling back from earlier session highs. Crude oil prices have significantly declined.

23 de jul. de 2026, 19:36 UTC

Emergent BioSolutions Inc shares are lower, reflecting broader market trends amid negative earnings from major technology companies like Tesla and Alphabet.